[go: up one dir, main page]

AU2001288623A1 - Fxr modulators - Google Patents

Fxr modulators

Info

Publication number
AU2001288623A1
AU2001288623A1 AU2001288623A AU8862301A AU2001288623A1 AU 2001288623 A1 AU2001288623 A1 AU 2001288623A1 AU 2001288623 A AU2001288623 A AU 2001288623A AU 8862301 A AU8862301 A AU 8862301A AU 2001288623 A1 AU2001288623 A1 AU 2001288623A1
Authority
AU
Australia
Prior art keywords
fxr modulators
fxr
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288623A
Inventor
Joshua P. Gergely
Jonathan Houze
Frank Kayser
Sharon Mckendry
Bei Shan
Yi Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of AU2001288623A1 publication Critical patent/AU2001288623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/021,2-Thiazines; Hydrogenated 1,2-thiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001288623A 2000-09-05 2001-08-31 Fxr modulators Abandoned AU2001288623A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23058500P 2000-09-05 2000-09-05
US60/230,585 2000-09-05
US25809200P 2000-12-22 2000-12-22
US60/258,092 2000-12-22
PCT/US2001/027239 WO2002020463A2 (en) 2000-09-05 2001-08-31 Fxr modulators

Publications (1)

Publication Number Publication Date
AU2001288623A1 true AU2001288623A1 (en) 2002-03-22

Family

ID=26924371

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288623A Abandoned AU2001288623A1 (en) 2000-09-05 2001-08-31 Fxr modulators

Country Status (3)

Country Link
US (2) US6777446B2 (en)
AU (1) AU2001288623A1 (en)
WO (1) WO2002020463A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119958A1 (en) * 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
JP4021327B2 (en) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Steroids as agonists for FXR
ATE521599T1 (en) 2001-12-21 2011-09-15 X Ceptor Therapeutics Inc HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS
CA2471311A1 (en) 2001-12-21 2003-07-24 Pharmacia Corporation Aromatic thioether liver x-receptor modulators
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
US6822120B2 (en) * 2002-05-24 2004-11-23 Pharmacia Corporation Sulfone liver X-receptor modulators
US6900244B2 (en) * 2002-05-24 2005-05-31 Pharmacia Corporation Anilino liver X-receptor modulators
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
AU2004303461B2 (en) * 2003-12-23 2011-04-28 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
EP1734970B1 (en) 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
US7276606B2 (en) 2004-04-30 2007-10-02 4Sc Ag Phenantridine analogues and uses thereof
EP1652841A1 (en) * 2004-04-30 2006-05-03 Switch Biotech Aktiengesellschaft Novel phenantridine analogues and their use as inhibitors of hyperproliferation of T cells and/or keratinocytes
AR052308A1 (en) * 2004-07-16 2007-03-14 Lundbeck & Co As H DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARILAMINE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20100055066A1 (en) * 2004-10-15 2010-03-04 Kazuo Suzuki Agent for prophylactic and/or therapeutic treatment of diabetes
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
US7618956B2 (en) * 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (en) * 2005-06-17 2007-06-20 Lundbeck & Co As H DERIVATIVES OF BENZO (B) FURANO AND BENZO (B) THIOPHEN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE REINFORCEMENT OF AMINA BOSS NEUTRANTS.
TW200817319A (en) 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
EP1886685A1 (en) * 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CN103251579B (en) 2006-08-24 2016-12-28 田纳西大学研究基金会 Substituted N-anilid and using method thereof
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
NZ591366A (en) 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
ES2458168T3 (en) 2008-11-19 2014-04-30 Intercept Pharmaceuticals, Inc. TGR5 modulators and their method of use
JP2012515760A (en) 2009-01-20 2012-07-12 ファイザー・インク Substituted pyrazinonamide
CN102388038B (en) 2009-03-11 2014-04-23 辉瑞大药厂 Benzofuryl derivatives useful as glucokinase activators
HUE024874T2 (en) 2009-09-03 2016-02-29 Bioenergenix Heterocyclic compounds for inhibiting PASK
FR2962649B1 (en) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers TREATMENT OF A PATHOLOGY RELATED TO AN EXCESSIVE EFFECT OF TNF WITH A BENZENE SULFONAMIDE COMPOUND
ES2677668T3 (en) 2010-11-16 2018-08-06 Texas Heart Institute Agonists that improve the binding of cells expressing integrin to integrin receptors
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP3789394A1 (en) 2012-06-19 2021-03-10 Intercept Pharmaceuticals, Inc. Crystalline forms c of obeticholic acid
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9604916B2 (en) 2012-07-13 2017-03-28 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP3167887B1 (en) * 2014-07-07 2021-03-24 Chen, Kuenfeng Aryl amine substituted quinoxaline used as anticancer drugs
EP3253382B1 (en) 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
TN2018000188A1 (en) 2015-12-15 2019-10-04 Astrazeneca Ab Isoindole compounds
EP3414256B1 (en) 2016-02-10 2022-01-19 Dr. Reddy's Laboratories Limited Purification process involving amine salt of obeticholic acid
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
BR112020021469A2 (en) * 2018-04-20 2021-01-19 Virginia Tech Intellectual Properties, Inc. IMIDAZOPYRIDINES USEFUL AS MITOCHONDRIAL DETACHERS
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
GB201909659D0 (en) 2019-07-04 2019-08-21 Aberystwyth Univ Anti-infective compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL123536C (en) * 1963-07-09
US3985804A (en) * 1973-08-18 1976-10-12 Kumiai Chemical Industry Co., Ltd. Agricultural substituted 2-methylbenzanilide germicide
DE2525855C3 (en) * 1974-06-12 1978-06-22 Kumiai Chemical Industry Co., Ltd., Tokio Substituted benzoic anilides and an agent containing these compounds
US4279887A (en) * 1978-11-29 1981-07-21 Medi-Physics, Inc. Amides useful as brain imaging agents
US5470982A (en) * 1988-01-20 1995-11-28 Bayer Aktiengesellschaft Disubstituted pyridines
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
EA003924B1 (en) * 1998-09-23 2003-10-30 Туларик, Инк. Arylsulfonanilide ureas
JP2002532729A (en) 1998-12-23 2002-10-02 グラクソ グループ リミテッド Assay for nuclear receptor ligands
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity

Also Published As

Publication number Publication date
US20020120137A1 (en) 2002-08-29
WO2002020463A2 (en) 2002-03-14
WO2002020463A3 (en) 2003-08-21
US20040176426A1 (en) 2004-09-09
US7511043B2 (en) 2009-03-31
US6777446B2 (en) 2004-08-17

Similar Documents

Publication Publication Date Title
AU2001288623A1 (en) Fxr modulators
AU2001262847A1 (en) Language-understanding
AU2001292739A1 (en) 1-oxorapamycins
AU2002211620A1 (en) Autoanastomosis
AU2000235960A1 (en) Lxr modulators
AU2001254546A1 (en) Aminopiperidines
AU2001220246A1 (en) Neckphone
AU2001296577A1 (en) Chlorophyllases
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2002211128A1 (en) Step-bike
AU2001258924A1 (en) Microsatellite-aflp
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001291876A1 (en) Triazolo-epothilones
EP1368891B8 (en) Iq modulator
AU2001226668A1 (en) Crankshaft-starter-generator
AU2002214354A1 (en) Neck-phone
AU2001262711A1 (en) Cytoprotectors
AU4620300A (en) Can
AU2001260192A1 (en) Glycinamides
AU2001295713A1 (en) Blast-processing
AU2001284173A1 (en) Calycins
AU2001275014A1 (en) Imidazoloisoquinolines